What evidence is available from recent trials regarding the benefits of aspirin in preventing nonfatal myocardial infarction (MI) and stroke?
Recent trials show that the relative benefits of aspirin in preventing nonfatal myocardial infarction (MI) and stroke, with a trend towards lower mortality, have been less evident. Absolute risk for atherosclerotic cardiovascular disease (ASCVD) events typically exceeds that of serious bleeding, and the number needed to treat to prevent an ASCVD event is lower than the number needed to harm to cause bleeding.